3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Terminated
1
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Ovarian Neoplasms
9
Neoplasms
3
Endometrial Neoplasms
3
Breast Neoplasms
3
Prostatic Neoplasms
2
Pancreatic Neoplasms
2
Head and Neck Neoplasms
2
Esophageal Neoplasms
2
Uterine Cervical Neoplasms
1
Urologic Neoplasms
1
Thrombocytopenia
1
Stomach Neoplasms
1
Solid Tumor, Adult
1
Recurrence
1
Rectal Neoplasms
1
Osteosarcoma
1
Oligodendroglioma
1
Neutropenia
1
Neuroblastoma
1
Neoplasm Metastasis
1
Melanoma
1
Lung Neoplasms
1
Glioma
1
Glioblastoma
1
Fallopian Tube Neoplasms
1
Cystadenocarcinoma, Serous
1
Colonic Neoplasms
1
Carcinoma, Renal Cell
1
Biliary Tract Neoplasms
1
Astrocytoma
1
Interventions
pembrolizumab
51
Ipilimumab
49
Cyclophosphamide
43
Nivolumab
40
aldesleukin
30
Interleukin-2
23
Vemurafenib
20
fludarabine
19
Temozolomide
18
fludarabine phosphate
15
dabrafenib
15
trametinib
12
Radiosurgery
10
Dacarbazine
10
CTLA-4 Antigen
10
spartalizumab
9
cobimetinib
9
binimetinib
9
Radiotherapy
9
poly ICLC
7
encorafenib
7
Paclitaxel
7
atezolizumab
6
Introns
6
Biopsy
6
montanide ISA 51
5
Carboplatin
5
epacadostat
4
MART-1 Antigen
4
Interferon alpha-2
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Melanoma
×
niraparib
×
Clear all
NCT05169437
2025-10-29
PAVO
Tempus AI
Phase 2
Terminated
22 enrolled
17 charts